KAS
BCRX icon

Kestra Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Kestra Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
13,110
-2,630
-17% -$23.8K ﹤0.01% 3153
2026
Q1 		$150K Buy
15,740
+2,680
+21% +$20.8K ﹤0.01% 2987
2025
Q4 		$102K Sell
13,060
-72
-0.5% -$521 ﹤0.01% 3407
2025
Q3 		$99.7K Buy
13,132
+432
+3% +$3.6K ﹤0.01% 2820
2025
Q2 		$114K Sell
12,700
-15
-0.1% -$140 ﹤0.01% 2726
2025
Q1 		$95.4K Sell
12,715
-100
-0.8% -$807 ﹤0.01% 2595
2024
Q4 		$96.4K Buy
+12,815
New +$97.3K ﹤0.01% 2574
2023
Q4 		– Sell
-18,779
Closed -$133K – 2274
2023
Q3 		$133K Sell
18,779
-7,300
-28% -$52.5K ﹤0.01% 1990
2023
Q2 		$184K Buy
26,079
+2,150
+9% +$17.3K ﹤0.01% 1918
2023
Q1 		$200K Buy
23,929
+2,395
+11% +$23.1K ﹤0.01% 1843
2022
Q4 		$247K Buy
21,534
+7,220
+50% +$90K ﹤0.01% 1876
2022
Q3 		$180K Buy
+14,314
New +$184K ﹤0.01% 1899

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Kestra Advisory Services's BCRX Position: Q2 2026 in Review

Kestra Advisory Services reduced its BioCryst Pharmaceuticals (BCRX) stake by 17% in Q2 2026, selling an estimated $23.8K and leaving 13,110 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Kestra Advisory Services first reported a position in BCRX in Q3 2022 and has held it in 12 quarters since. The position peaked at $247K in Q4 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Kestra Advisory Services held 13,110 shares of BioCryst Pharmaceuticals worth $131K as of Q2 2026.
  • Kestra Advisory Services sold 2,630 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $23.8K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3153 holding.
  • Kestra Advisory Services first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • Kestra Advisory Services's BioCryst Pharmaceuticals position peaked at $247K in Q4 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.